Variations of Urothelial Tight Junction Protein (Occludin) and its Correlation with Bladder Dose in Patients under Prostate Radiotherapy

Document Type : Original Article (s)

Authors

1 PhD Student, Department of Medical Physics, Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Radiation Oncologist, Department of Radiation Oncology, Milad Hospital, Isfahan, Iran

3 Professor, Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: The aim of this study was to assess the effects of fractionated radiotherapy (RT) on expression of urothelial tight junction protein (occluding) in patients under prostate radiotherapy. Finding a correlation between occludin expression and bladder dose for patients undergoing prostate conformal external radiotherapy was the second aim.Methods: Urine samples of 64 patients under prostate radiotherapy were collected before and at regular intervals during and 3 months after radiotherapy. Occludin expression analysis of the collected urine samples was performed using chemical methods. The effective uniform dose to bladder was derived from the individually produced dose treatment plan of the patients.Findings: There was a significant change in urine occludin level after initiation of the radiotherapy course compared to the baseline urine samples (P = 0.040). The threshold bladder dose that caused significant change in occludin level was 25.5 Gy (P = 0.046). This bladder dose was occurred after the 15th radiotherapy session. In addition, change in urine occludin level was compatible with frequency, urgency, and dysuria (P < 0.050).Conclusion: Significant change in occludin expression occurred during prostate radiotherapy. Our findings suggest that increase in occludin expression level of the bladder wall can be used as early markers of bladder complications for patients under prostate radiotherapy.

Keywords

References

  1. Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer; results from a prospective, population-based randomized controlled trial. Eur Urol 2007; 51(3): 659-64.
  2. Potters L, Morgenstern C, Calugaru E, Fearn P, Jassal A, Presser J, et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005; 173(5): 1562-6.
  3. Cheung MR, Tucker SL, Dong L, de Crevoisier R, Lee AK, Frank S, et al. Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2007; 67(4): 1059-65.
  4. Abdolahi M, Shahbazi-Gahrouei D, Laurent S, Sermeus C, Firozian F, Allen BJ, et al. Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer. Contrast Media Mol Imaging 2013; 8(2): 175-84.
  5. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute (NCI). Common terminology criteria for adverse events (CTCAE). Version 4.02. Rockville, MA: NCI; 2009.
  6. Shahbazi-Gahrouei D, Gookizadeh A , Abdollahi M. Comparison of conventional radiotherapy techniques with different energies in treating prostate cancer, employing a designed pelvis phantom. J Med Sci 2008; 8(4): 429-32.
  7. Dorr W, Hendry JH. Consequential late effects in normal tissues. Radiother Oncol 2001; 61(3): 223-31.
  8. Fiorino C, Valdagni R, Rancati T, Sanguineti G. Dose-volume effects for normal tissues in external radiotherapy: pelvis. Radiother Oncol 2009; 93(2): 153-67.
  9. Georg P, Boni A, Ghabuous A, Goldner G, Schmid MP, Georg D, et al. Time course of late rectal- and urinary bladder side effects after MRI-guided adaptive brachytherapy for cervical cancer. Strahlenther Onkol 2013; 189(7): 535-40.
  10. Sutani S, Ohashi T, Sakayori M, Kaneda T, Yamashita S, Momma T, et al. Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy. Radiother Oncol 2015; 117(2): 270-6.
  11. Lee JD, Lee MH. Decreased expression of zonula occludens-1 and Occludin in the bladder urothelium of patients with interstitial cystitis/painful bladder syndrome. J Formos Med Assoc 2014; 113(1): 17-22.
  12. Dorr W. Radiation effect in normal tissue - principles of damage and protection. Nuklearmedizin 2010; 49(Suppl 1): S53-S58. [In German].
  13. Shahbazi-Gahrouei D. Radiobiological modeling in radiation oncology. J Radiobiol 2014; 1(1): 17-8.
  14. Joiner MC, van der Kogel A. Basic clinical radiobiology. 4th ed. Boca Raton, FL: CRC Press; 2009.
  15. Thornqvist S, Hysing LB, Tuomikoski L, Vestergaard A, Tanderup K, Muren LP, et al. Adaptive radiotherapy strategies for pelvic tumors - a systematic review of clinical implementations. Acta Oncol 2016; 55(8): 943-58.
Journal of Isfahan Medical School
Volume 35, Issue 428 - Serial Number 428
March and April 2017
Pages 482-487

Files

History

  • Receive Date: 06 February 2017
  • Revise Date: 27 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics